Welcome to our dedicated page for Sensus Healthcare news (Ticker: SRTS), a resource for investors and traders seeking the latest updates and insights on Sensus Healthcare stock.
Sensus Healthcare, Inc. (Nasdaq: SRTS) is a medical device company that focuses on non-invasive and minimally-invasive treatments for oncological and non-oncological skin conditions using superficial radiotherapy (SRT and IG-SRT). The SRTS news page on Stock Titan aggregates company announcements, press releases and market updates so readers can follow how Sensus’ technology, reimbursement environment and commercial activities evolve over time.
Recent news highlights include recognition of Sensus Healthcare as a global pioneer in non-invasive treatments for skin cancer and keloids, updates on clinical evidence for its SRT systems, and developments in reimbursement policy. The company has reported that the Centers for Medicare & Medicaid Services established dedicated CPT codes specific to superficial radiotherapy for non-melanoma skin cancer, which Sensus describes as a pivotal moment for its platform and strategy. News items also cover growth in treatment volumes under its Fair Deal Agreement program and shipments of SRT systems to both U.S. and international customers.
Investors and healthcare professionals can use this news feed to track quarterly financial results, board and governance changes, conference participation, and recognition such as Sensus Healthcare’s inclusion in TIME’s America’s Growth Leaders of 2026 ranking. Clinical and scientific updates, including published studies on the use of SRT for keloids, provide additional context on how the company’s technology is being used in practice.
By reviewing the SRTS news stream regularly, readers can see how Sensus Healthcare communicates its progress in radiation oncology technology, reimbursement milestones, commercial expansion and clinical validation of its superficial radiotherapy solutions.
Sensus Healthcare (Nasdaq: SRTS) announced on November 12, 2025 the appointment of Eric Sachetta to its Board of Directors to fill the vacancy left by the passing of long-serving director Bill McCall. Sachetta is a seasoned financial executive and currently Chief Wealth Services Officer of Sachetta, LLC, where he oversees advisory strategy and wealth management operations since 2022.
He has prior leadership experience founding The E TEAM and authored a personal leadership curriculum. Sachetta holds a B.S. in Corporate Finance & Accounting from Bentley University and professional credentials including CFP, ChFC, TPCP and a Series 65 license. Company leadership said they expect his financial and people-focused experience to support strategic growth and SRT technology expansion.
Sensus Healthcare (NASDAQ: SRTS) reported third quarter 2025 results on November 6, 2025: revenues $6.9M, net loss $0.9M (‑$0.06/share), and Adjusted EBITDA ‑$2.4M. CMS established dedicated CPT coding validating SRT for non‑melanoma skin cancer. The company shipped 16 SRT systems (three to China), reported FDA treatment volume +20% QoQ (+52% vs Q1), and published clinical data on SRT plus punch excision for keloids. Cash was $24.5M at quarter end with no debt and ~100 systems in inventory.
Sensus Healthcare (Nasdaq: SRTS) was named to TIME’s America’s Growth Leaders of 2026 on November 6, 2025, ranking No. 72 among 500 U.S. publicly traded companies. The ranking reflects five-year revenue growth, financial stability, and stock performance. The company highlighted continued commercial momentum, global expansion, and growing adoption of its superficial radiation therapy (SRT and IG-SRT) systems for non-melanoma skin cancer and keloids.
Management emphasized the award as recognition of sustained growth, customer service, and clinical outcomes supporting adoption over the past 15 years.
Sensus Healthcare (Nasdaq: SRTS) announced that CMS published the first-ever dedicated CPT codes for superficial radiotherapy (SRT and IG-SRT) to treat non‑melanoma skin cancer (NMSC) in the 2026 Physician Fee Schedule.
The update signals CMS validation of SRT as a standalone modality, reports an increase in reimbursement per fraction of more than 300% versus current codes, and is described as strengthening reimbursement certainty, physician economics, and patient access to non‑surgical SRT options. Management says the coding change supports expansion into dermatology and radiation oncology settings and should accelerate adoption of the SRT platform.
Sensus Healthcare (Nasdaq: SRTS) announced the passing of longtime director William “Bill” McCall on October 31, 2025. McCall supported Sensus since 2009, led the Company’s initial capital raise in 2010, and joined the board in 2015, providing counsel and leadership throughout his tenure.
Management praised his financial acumen, 50+ year advisory career, charitable work in Tennessee, and said the Board will honor his memory and communicate any governance changes in due course.
Sensus Healthcare (Nasdaq: SRTS) will report third quarter 2025 financial results on Thursday, November 6, 2025. Management will host a business update conference call beginning at 4:30 p.m. Eastern to review results and answer questions.
Participants are encouraged to pre-register to receive a unique dial-in to bypass the operator; pre-registration is available up to and after the call start time. Live access is also available by dialing 844-481-2811 (U.S./Canada) or 412-317-0676 (International). The call will be webcast live and archived in the Investor Relations section at www.sensushealthcare.com.
A telephone replay will be available through December 6, 2025 by dialing U.S. toll free 877-344-7529, Canada toll free 855-669-9658, or International 412-317-0088 and entering replay code 5165150.
Sensus Healthcare (NASDAQ: SRTS) announced positive results from a study published in Dermatologic Therapy demonstrating the effectiveness of combining their superficial radiotherapy (SRT) technology with punch excision for treating keloids. The study, conducted at the Hospital for Skin Diseases in Nanjing, China, evaluated 60 patients and showed statistically significant improvements in pain, itching, thickness, and irregularity of keloid scars after one year.
The research highlights that keloids, affecting 4% to 16% of the population, particularly impact individuals with higher melanin levels. The combination therapy showed no severe adverse reactions, supporting SRT's safety profile and its potential as a treatment option for this serious medical condition that disproportionately affects African, Hispanic, and Asian populations.
Sensus Healthcare (NASDAQ:SRTS) reported Q2 2025 financial results, with revenues of $7.3 million, down from $9.2 million in Q2 2024. The company shipped 19 SRT systems, including four to China, while experiencing a 27% increase in FDA treatment volume over Q1. The quarter resulted in a net loss of $1.0 million ($0.06 per share).
Key developments include signing five new Fair Deal Agreements, receiving MDSAP certification for their SRT product portfolio, and partnering with Radiology Oncology Systems (ROS) for distribution. The company maintained a strong financial position with $22.2 million in cash and no debt. A proposed Medicare Physician Fee Schedule change could positively impact SRT technology adoption starting January 2026.
Sensus Healthcare (NASDAQ: SRTS), a medical device company focused on non-invasive treatments for skin conditions, has scheduled its Q2 2025 earnings release for August 7, 2025. The company will host a conference call at 4:30 PM Eastern time to discuss financial results and provide a business update.
Participants can pre-register for the call using a dedicated link to receive a unique dial-in number. Alternative dial-in options include 844-481-2811 (U.S./Canada) and 412-317-0676 (International). A webcast will be available live and archived in the Investor Relations section of the company's website. A telephone replay will be accessible until September 7th using replay code 8187211.
Sensus Healthcare (NASDAQ: SRTS) has achieved Medical Device Single Audit Program (MDSAP) certification for its complete portfolio of superficial radiation therapy (SRT) systems, including the SRT-100®, SRT-100+™, and SRT-100 Vision™.
The MDSAP certification streamlines regulatory compliance by allowing a single audit to satisfy requirements across multiple jurisdictions including the FDA, Health Canada, Brazil's ANVISA, Japan's PMDA, and Australia's TGA. This certification is expected to accelerate the company's international expansion by simplifying regulatory processes and reducing approval timelines in key global markets.
Upon receiving FDA clearance, Sensus Healthcare's TransDermal Infusion (TDI) product is also anticipated to receive MDSAP certification, further enhancing its international commercial potential.